Your browser is no longer supported. Please, upgrade your browser.
InflaRx N.V.
Index- P/E- EPS (ttm)-1.33 Insider Own15.19% Shs Outstand44.19M Perf Week3.11%
Market Cap114.43M Forward P/E- EPS next Y-0.93 Insider Trans0.00% Shs Float34.32M Perf Month-11.67%
Income-37.70M PEG- EPS next Q-0.24 Inst Own33.30% Short Float0.09% Perf Quarter-28.38%
Sales- P/S- EPS this Y38.70% Inst Trans0.93% Short Ratio0.12 Perf Half Y-52.85%
Book/sh4.85 P/B0.55 EPS next Y0.00% ROA-28.90% Target Price- Perf Year-46.14%
Cash/sh3.76 P/C0.70 EPS next 5Y- ROE-32.10% 52W Range2.42 - 6.88 Perf YTD-47.32%
Dividend- P/FCF- EPS past 5Y-43.00% ROI- 52W High-63.37% Beta0.47
Dividend %- Quick Ratio17.70 Sales past 5Y- Gross Margin- 52W Low4.13% ATR0.15
Employees49 Current Ratio17.70 Sales Q/Q- Oper. Margin- RSI (14)28.55 Volatility5.87% 5.21%
OptionableYes Debt/Eq0.00 EPS Q/Q42.60% Profit Margin- Rel Volume0.73 Prev Close2.65
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume245.81K Price2.52
Recom2.40 SMA20-10.73% SMA50-13.98% SMA200-39.80% Volume136,968 Change-4.91%
Mar-11-21Upgrade Guggenheim Neutral → Buy $16
Nov-06-20Upgrade SVB Leerink Mkt Perform → Outperform $7 → $10
Oct-08-20Initiated H.C. Wainwright Buy $11
Jun-17-20Initiated BTIG Research Buy $12
Apr-30-20Upgrade Raymond James Mkt Perform → Outperform
Jun-05-19Downgrade SunTrust Buy → Hold $55 → $5
Jun-05-19Downgrade Robert W. Baird Outperform → Neutral $58 → $6
Jun-05-19Downgrade JP Morgan Overweight → Underweight $67 → $9
Jun-05-19Downgrade Guggenheim Buy → Neutral $65 → $6
Jun-05-19Downgrade BMO Capital Markets Outperform → Market Perform $5
Jan-29-19Initiated Robert W. Baird Outperform
Dec-10-18Initiated Credit Suisse Outperform
Jul-13-18Initiated BMO Capital Markets Outperform $45
Jun-28-18Initiated SunTrust Buy $55
Jun-28-18Initiated Raymond James Outperform
Feb-08-18Initiated B. Riley FBR, Inc. Buy $40
Jun-17-21 07:30AM  
Jun-08-21 07:30AM  
May-30-21 05:22AM  
May-21-21 07:30AM  
May-12-21 07:30AM  
May-11-21 04:30PM  
Apr-15-21 07:30AM  
Mar-25-21 06:30AM  
Mar-03-21 07:30AM  
Mar-01-21 04:01PM  
Feb-25-21 08:30AM  
Feb-24-21 04:01PM  
Feb-11-21 09:11AM  
Jan-11-21 07:30AM  
Jan-07-21 07:30AM  
Jan-05-21 07:30AM  
Dec-08-20 11:35AM  
Dec-02-20 08:30PM  
Nov-12-20 07:02AM  
Oct-29-20 07:00AM  
Sep-30-20 04:22AM  
Sep-17-20 07:30AM  
Sep-14-20 07:30AM  
Aug-06-20 07:30AM  
Jul-30-20 07:30AM  
Jul-24-20 08:55AM  
Jul-21-20 07:30AM  
Jul-16-20 11:48AM  
Jul-09-20 07:33AM  
Jun-25-20 04:05PM  
Jun-17-20 07:30AM  
Jun-11-20 08:30AM  
May-29-20 11:10AM  
May-28-20 08:31AM  
May-21-20 07:30AM  
Apr-29-20 08:00AM  
Apr-14-20 07:30AM  
Apr-01-20 04:18PM  
Mar-31-20 04:15PM  
Mar-06-20 10:49AM  
Feb-26-20 07:30AM  
Feb-19-20 08:00AM  
Jan-09-20 07:30AM  
Dec-20-19 07:45PM  
Nov-07-19 07:30AM  
Oct-17-19 08:43AM  
Aug-14-19 04:05PM  
Jul-19-19 12:43PM  
Jul-18-19 04:01PM  
Jun-29-19 11:31PM  
Jun-13-19 10:18AM  
Jun-05-19 04:18PM  
May-23-19 09:15AM  
May-14-19 08:00AM  
May-03-19 10:12AM  
Apr-10-19 08:45AM  
Mar-28-19 08:30AM  
Mar-12-19 07:37AM  
Feb-27-19 08:30AM  
Feb-25-19 07:30AM  
Feb-14-19 08:30AM  
Feb-06-19 07:00AM  
Jan-03-19 08:30AM  
Dec-22-18 03:43AM  
Dec-19-18 08:30AM  
Nov-21-18 08:30AM  
Nov-08-18 02:30AM  
Oct-30-18 07:30AM  
Oct-23-18 09:15AM  
Sep-21-18 08:30AM  
Aug-28-18 07:30AM  
Aug-09-18 07:00AM  
Jun-28-18 07:30AM  
Jun-05-18 07:30AM  
May-17-18 07:30AM  
May-08-18 10:42AM  
May-03-18 08:28PM  
May-02-18 07:44AM  
Mar-29-18 07:00AM  
Mar-12-18 08:40AM  
Mar-08-18 08:23AM  
Feb-06-18 07:52AM  
Feb-01-18 09:55AM  
Jan-23-18 01:53PM  
Jan-15-18 10:51AM  
Jan-09-18 08:56AM  
Jan-04-18 01:47PM  
Nov-10-17 08:05AM  
Nov-08-17 01:31PM  
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.